For decades, non-cystic fibrosis bronchiectasis (NCFB) patients had no dedicated, FDA-approved therapy — relying instead on antibiotics, airway clearance techniques, and supportive care to manage a chronic and often debilitating condition. That changed with the arrival of brinsupri (brensocatib), Insmed's first-in-class oral therapy that has become the first and only approved treatment...